Loading...
Market
Maximum number of lesions in animals vaccinated with Moderna's mRNA-1769 in the next animal study by June 30, 2025?
2
Resolution / Starting Odds
0-50 lesions • 25%
51-100 lesions • 25%
101-200 lesions • 25%
More than 200 lesions • 25%
Publication of study results in scientific journals or press releases from Moderna
Story
Moderna's mRNA-1769 Mpox Vaccine Shows Promising Results in Animal Study Amid Africa Outbreaks
Sep 4, 2024, 03:24 PM
Moderna has reported encouraging results from an animal study on its experimental mRNA mpox vaccine, mRNA-1769. The study, conducted on non-human primates, demonstrated that the Moderna vaccine provided stronger protection compared to the existing Jynneos vaccine. Unvaccinated animals developed up to 1,448 lesions, while those vaccinated with Jynneos had a maximum of 607 lesions, and those immunized with Moderna's mRNA vaccine had a maximum of 54 lesions. The vaccine candidate contains mRNA molecules that code for four proteins found on the surface of the monkeypox virus. This development comes as mpox outbreaks continue to spread in Africa. A Phase 1/2 human trial of the vaccine is already underway.
View original story
Similar markets
Effective • 25%
Moderately Effective • 25%
Ineffective • 25%
Halted • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
Yes • 50%
No • 50%
Less than 1 million • 25%
1-5 million • 25%
5-10 million • 25%
More than 10 million • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Positive • 25%
Negative • 25%
Mixed • 25%
Not published • 25%
None • 25%
Mild • 25%
Moderate • 25%
Severe • 25%
Less than 50% • 25%
50% to 70% • 25%
70% to 90% • 25%
More than 90% • 25%
